NT 10-Q 1 cenb20220512_nt10q.htm FORM NT 10-Q cenb20220512_nt10q.htm
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
 

FORM 12b-25

SEC FILE NUMBER

 
   

000-55557
     
   

CUSIP NUMBER
 

NOTIFICATION OF LATE FILING

  

 

 

(Check one):

☐ Form 10-K           ☐ Form 20-F           ☐ Form 11-K           ☒ Form 10-Q           ☐ Form 10-D
☐ Form N-CEN       ☐ Form N-CSR
   
 

For Period Ended: March 31, 2022

 

☐ Transition Report on Form 10-K
☐ Transition Report on Form 20-F
☐ Transition Report on Form 11-K
☐ Transition Report on Form 10-Q
 
For the Transition Period Ended: ____________________

 

Read Instruction (on back page) Before Preparing Form. Please Print or Type. 
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. 

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

 

 

 
 

 

PART I — REGISTRANT INFORMATION

 

 

CEN BIOTECH, INC.

Full Name of Registrant
 
 

Former Name if Applicable
 

300-3295 Quality Way

Address of Principal Executive Office (Street and Number)
 

Windsor, Ontario, Canada N8T 3R9

City, State and Zip Code

 

 
 

 

PART II — RULES 12b-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

 

 

 

  

(a)

The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
         
 

☒

  

(b)

The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
         
     

(c)

The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

 

PART III — NARRATIVE

 

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period. (Attach extra Sheets if Needed)

 

CEN Biotech, Inc. (the “Company”) has determined that it is unable to file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 (the “Form 10-Q”) by May 16, 2022, the original due date for such filing, without unreasonable effort or expense because it requires additional time to complete its financial statements. This delay principally relates to a recent change by the Company in both its auditors and its accountants. The Company’s Board of Directors decided to change auditors after the most recent year end and it took some time to bring the new auditors up to speed and get the information to them for review. The Company also changed accountants as well which added to the delay. The Company expects that it will file the Form 10-Q no later than the fifth calendar day following the prescribed filing date.

 

PART IV — OTHER INFORMATION

 

           

(1)

Name and telephone number of person to contact in regard to this notification
 
 

Brian S. Payne

  

519

  

419-4958
 

(Name)

  

(Area Code)

  

(Telephone Number)
 

(2)

Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
 
 

Yes  ☒     NO  ☐
 
   
 

(3)

Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
 
 

Yes  ☐     NO  ☒
 
 

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

 
 

 

CEN Biotech, Inc.

(Name of Registrant as Specified in Charter)

 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date:  

May 12, 2022

  

By:

/s/ Brian S. Payne
     

Name:

Brian S. Payne
     

Title:

Chief Executive Officer